Varo Money Inc., a San Francisco-based mobile banking company, completed a $240 million Series D round. Gallatin Point Capital and The Rise Fund co-led the investment and were joined by HarbourVest Partners and Progressive Insurance.
Prilenia Therapeutics BV, an Israel- and The Netherlands-based startup developing treatments for neurodegenerative and neurodevelopmental disorders, secured $62.5 million in Series A financing led by Forbion. New investors Morningside Venture Investments and Sectoral Asset Management joined in the round, along with existing backers Talisman Capital Partners and Genworks 2. In addition to the funding, Michael R. Hayden was appointed chief executive of the company. He was previously president of global R&D and chief scientific officer at Teva Pharmaceuticals.
Tembici, a São Paulo-based electric bike startup, picked up $47 million in Series B funding. Valor Capital Group and Redpoint eventures led the round, which included participation from International Finance Corp. and Joá Investimentos. Redpoint’s Romero Rodrigues and Valor’s Scott Sobel will join the company’s board.
TAE Life Sciences, a Foothill Ranch, Calif.-based radiation therapy startup developing novel treatments for cancer, landed a $30 million Series B round from investors including Artis Ventures.
Verne Global, a London-based developer of energy-efficient data centers, nabbed a $27 million investment from Wellcome Trust, Novator Partners, Stefnir and General Catalyst.
PlushCare, a San Francisco-based virtual primary-care platform, secured $23 million in Series B financing. Transformation Capital led the round, with participation from GGV Capital, WTI and others. Mike Dixon, managing partner at Transformation, joined the board.
MessageGears, an Atlanta-based customer marketing platform, closed a $12 million round of growth funding led by Argentum and Bridge Bank. Walter H. Barandiarán, managing partner at Argentum, joined the board.
Bigfoot Biomedical Inc., a Milpitas, Calif.-based developer of insulin dosing technology for diabetes patients, added $10 million in Series C funding to close the round with $55 million. Abbott Laboratories led the round, with participation from Quadrant Capital Advisors, Senvest Capital, Janus Henderson, Cormorant Asset Management and Smile Group. Additionally, co-founder Bryan Mazlish will transition from president to executive board director focusing on the company’s strategy and governance initiatives. Joy Mashaal of Senvest will join the board.
Lili, a New York-based banking app designed for freelance workers, was seeded with a $10 million investment. Group 11 led the round, which included contributions from Foundation Capital, AltaIR Capital, Primary Venture Partners and Torch Capital.
Shorla Pharma Ltd., an Irish developer of oncology drugs with a focus on rare, orphan and pediatric cancers, collected an $8.3 million Series A investment. Seroba Life Sciences led the round, which included support from Enterprise Ireland and others. Alan O'Connell, a partner at Seroba, joined the board.
Vara, a Berlin-based breast cancer screening startup, raised a €6.5 million ($7 million) Series A round. Omers Ventures led the investment, with participation from Merantix, Think.Health, Soleria Capital and Plug and Play. Bryony Marshall, associate director at Omers, will join the board.
Re-Vana Therapeutics Ltd., a Northern Ireland-based startup developing therapeutics for ocular diseases, closed $3.3 million in pre-Series A financing from ExSight Ventures, InFocus Capital Partners, TechStart Ventures, Clarendon Fund Managers, Qubis Ltd. and Visionary Ventures. Garrett Hamontree of Visionary and James Murray of ExSight joined the board.
|